TRADING UPDATES: East Star Verkhuba update; BSF distribution deal
11th Aug 2026 18:23
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
| Price | 1.10p on 10-09-2026 at 18:35:10 |
|---|---|
| Change | 0.00p 0% |
| Buy | 1.20p |
| Sell | 1.00p |
| Last Trade: | Buy 200,000.00 at 1.196p |
| Day's Volume: | 219,548 |
| Last Close: | 1.10p |
| Open: | 1.10p |
| ISIN: | GB0034330679 |
| Day's Range | 1.10p - 1.10p |
| 52wk Range: | 0.85p - 3.85p |
| Market Capitalisation: | £12.50m |
| VWAP: | 1.196p |
| Shares in Issue: | 1.14b |
Cellbxhealth (CLBX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 200,000 | 1.196p | Ordinary |
14:38:22 - 10-Sep-26 |
| Buy* | 5,000 | 1.196p | Ordinary |
08:48:12 - 10-Sep-26 |
| Buy* | 14,548 | 1.196p | Ordinary |
08:19:17 - 10-Sep-26 |
| Buy* | 100,000 | 1.198p | Ordinary |
12:02:22 - 09-Sep-26 |
| Buy* | 15,000 | 1.198p | Ordinary |
11:44:18 - 09-Sep-26 |
| Buy* | 67,968 | 1.196p | Ordinary |
11:37:57 - 09-Sep-26 |
| Buy* | 16,361 | 1.198p | Ordinary |
11:13:36 - 09-Sep-26 |
| Buy* | 100,000 | 1.198p | Ordinary |
10:22:36 - 09-Sep-26 |
| Buy* | 20,000 | 1.133p | Ordinary |
09:38:44 - 09-Sep-26 |
| Buy* | 119,414 | 1.198p | Ordinary |
09:32:17 - 09-Sep-26 |
Cellbxhealth (CLBX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Aug 2026 7:00 am | RNS | Parsortix CTCs used for Brain Cancer detection |
| 3rd Aug 2026 7:00 am | RNS | Parsortix CTCs used for ADC target assessment |
| 16th Jul 2026 7:00 am | RNS | Issue of Share Options |
| 15th Jul 2026 7:00 am | RNS | Q2 and First Half Year Results ended 30 June 2026 |
| 14th Jul 2026 9:46 am | RNS | Result of AGM |
| 14th Jul 2026 7:00 am | RNS | AGM Statement |
| 6th Jul 2026 4:45 pm | RNS | Directorate change |
| 22nd Jun 2026 7:00 am | RNS | Preliminary Results |
| 16th Jun 2026 7:00 am | RNS | Notice of Results |
| 29th May 2026 7:00 am | RNS | MSA with Global Pharmaceutical Company |